Compare GSK plc (GSK) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs T Rowe Price Group Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while T Rowe Price Group Inc trades at $105.6 (market cap $22.23B). The key difference: GSK plc is far larger — about 4.1× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.99%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and T Rowe Price Group Inc for 115 Days on average.
| GSK | TROW | |
|---|---|---|
Market Cap | $91.88B | $22.23B |
Volume | 7,730,529 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $61.18 | $121.68 |
52-Week Low | $43.24 | $86.19 |
Typical Hold Time | 93 Days | 115 Days |
Enterprise Value | $111.88B | $19.43B |
Dividend Yield | 3.9% | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
T. Rowe Price (TROW) trades at $105.16, up 1.05% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $7.31B revenue, 29.26% net margin, and attractive valuation at 10.46 P/E. Recent earnings show two beats out of three quarters, while assets under management reached $1.90T in August 2026 despite net outflows.
TROW presents a compelling value opportunity with solid dividend growth and reasonable valuation, though technical weakness and analyst caution warrant attention. The stock's 40-year dividend growth history and expanding ETF offerings through F/m Investments acquisition provide stability, while market volatility and fee pressure remain key risks for the asset management business.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
